JP2008528608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528608A5 JP2008528608A5 JP2007553225A JP2007553225A JP2008528608A5 JP 2008528608 A5 JP2008528608 A5 JP 2008528608A5 JP 2007553225 A JP2007553225 A JP 2007553225A JP 2007553225 A JP2007553225 A JP 2007553225A JP 2008528608 A5 JP2008528608 A5 JP 2008528608A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- immune response
- bacterial
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 230000028993 immune response Effects 0.000 claims 8
- 229930186217 Glycolipid Natural products 0.000 claims 7
- 230000001580 bacterial effect Effects 0.000 claims 7
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 4
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 claims 3
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 claims 3
- 241000606701 Rickettsia Species 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 210000000581 natural killer T-cell Anatomy 0.000 claims 3
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000000845 anti-microbial effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 125000006538 C11 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64815305P | 2005-01-28 | 2005-01-28 | |
| US60/648,153 | 2005-01-28 | ||
| PCT/US2006/002781 WO2006083671A2 (en) | 2005-01-28 | 2006-01-26 | Bacterial glycolipid activation of cd1d-restricted nkt cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008528608A JP2008528608A (ja) | 2008-07-31 |
| JP2008528608A5 true JP2008528608A5 (enExample) | 2009-03-19 |
| JP5053101B2 JP5053101B2 (ja) | 2012-10-17 |
Family
ID=36777772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553225A Expired - Fee Related JP5053101B2 (ja) | 2005-01-28 | 2006-01-26 | ＣＤ１ｄ−拘束ＮＫＴ細胞の細菌糖脂質による活性化 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9295722B2 (enExample) |
| EP (1) | EP1848813B1 (enExample) |
| JP (1) | JP5053101B2 (enExample) |
| AU (1) | AU2006211485B2 (enExample) |
| BR (1) | BRPI0607299A2 (enExample) |
| CA (1) | CA2593715C (enExample) |
| DK (1) | DK1848813T3 (enExample) |
| ES (1) | ES2423005T3 (enExample) |
| PL (1) | PL1848813T3 (enExample) |
| PT (1) | PT1848813E (enExample) |
| WO (1) | WO2006083671A2 (enExample) |
| ZA (1) | ZA200706208B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| WO2007118234A2 (en) | 2006-04-07 | 2007-10-18 | The Scripps Research Institute | Modified -galactosyl ceramides for staining and stimulating natural killer t cells |
| AU2007269299B2 (en) | 2006-06-30 | 2013-01-17 | Brigham Young University | Adjuvants and methods of use |
| WO2008128207A1 (en) * | 2007-04-13 | 2008-10-23 | Academia Sinica | Alpha-galactosyl ceramide analogs and their use as immunotherapies |
| US8916164B2 (en) | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
| AU2013202865B2 (en) * | 2007-11-07 | 2015-03-19 | Abivax | Increase of immune response and targeting by antigens and/or drug linkage |
| EP2058011A1 (en) * | 2007-11-07 | 2009-05-13 | Wittycell | Nkt cell activating gycolipids covalently bound antigens and/or drug |
| EP2060252A1 (en) | 2007-11-19 | 2009-05-20 | Wittycell | New formulation of galactosylceramide derivatives |
| BRPI0820960B8 (pt) * | 2007-12-05 | 2021-05-25 | Abivax | composição, composição farmacêutica, e uso da composição |
| US9220767B2 (en) | 2008-10-08 | 2015-12-29 | Abivax | Vaccine composition for use against influenza |
| AU2010217297A1 (en) | 2009-02-25 | 2011-10-20 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| JP6548579B2 (ja) * | 2012-12-06 | 2019-07-24 | ヴィクトリア リンク リミテッド | コンジュゲート化合物 |
| US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
| CN115666586A (zh) * | 2020-04-23 | 2023-01-31 | 加州大学评议会 | 通过激活iNKT细胞清除衰老细胞 |
| KR20230119224A (ko) * | 2020-12-18 | 2023-08-16 | 로레알 | 스핑고모나스 속 박테리아 추출물 |
| FR3117776B1 (fr) * | 2020-12-18 | 2024-03-08 | Oreal | Extrait de bactérie du genreSphingomonas |
| EP4301374A4 (en) | 2021-03-01 | 2025-09-10 | Deciduous Therapeutics Inc | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS |
| WO2024107463A1 (en) * | 2022-11-14 | 2024-05-23 | The Trustees Of Columbia University In The City Of New York | 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| TW261533B (enExample) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| ATE191916T1 (de) | 1992-10-22 | 2000-05-15 | Kirin Brewery | Neues sphingolglycolipid und verwendung davon |
| US5780441A (en) | 1993-04-15 | 1998-07-14 | Kirin Beer Kabushiki Kaisha | Sphingoglycolipid compounds and therapeutic uses thereof |
| CN1125449A (zh) | 1993-05-14 | 1996-06-26 | 萨依特尔有限公司 | 作为细胞粘附抑制剂的唾液基Lex类似物 |
| EP1520583B1 (en) | 1997-04-10 | 2009-01-28 | Kyowa Hakko Kirin Co., Ltd. | NKT cell-activating agents containing alpha-glycosylceramides |
| EP1011719A1 (en) * | 1997-09-12 | 2000-06-28 | Brigham & Women's Hospital | Synthetic antigens for cd1-restricted immune responses |
| US20030153514A1 (en) | 2000-04-28 | 2003-08-14 | Akikuni Yagita | Remedies for cancer |
| US20020071842A1 (en) * | 2000-06-05 | 2002-06-13 | Gumperz Jenny E. | Soluble CD1 compositions and uses thereof |
| EP1297017B1 (en) * | 2000-06-19 | 2012-06-13 | Beth Israel Deaconess Medical Center | Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| WO2001098317A2 (en) * | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| AU2002327338A1 (en) | 2001-07-25 | 2003-02-17 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| KR100549866B1 (ko) | 2001-08-22 | 2006-02-08 | 고려대학교 산학협력단 | 암치료 및 예방 제제 |
| CN1578667A (zh) | 2001-11-06 | 2005-02-09 | 东方癌症治疗株式会社 | 抗癌组合物 |
| WO2003105769A2 (en) * | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| WO2004094444A1 (en) | 2003-03-20 | 2004-11-04 | Brigham Young University | 6'-amino-6'-deoxygalactosylceramides |
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| GB0314682D0 (en) | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
| DK1786439T3 (da) | 2004-09-03 | 2010-07-12 | Univ Chicago | Fremgangsmåder til aktivering af NKT-celler |
| WO2007118234A2 (en) | 2006-04-07 | 2007-10-18 | The Scripps Research Institute | Modified -galactosyl ceramides for staining and stimulating natural killer t cells |
| AU2007269299B2 (en) | 2006-06-30 | 2013-01-17 | Brigham Young University | Adjuvants and methods of use |
-
2006
- 2006-01-26 DK DK06733921.8T patent/DK1848813T3/da active
- 2006-01-26 PL PL06733921T patent/PL1848813T3/pl unknown
- 2006-01-26 WO PCT/US2006/002781 patent/WO2006083671A2/en not_active Ceased
- 2006-01-26 ES ES06733921T patent/ES2423005T3/es not_active Expired - Lifetime
- 2006-01-26 AU AU2006211485A patent/AU2006211485B2/en not_active Ceased
- 2006-01-26 CA CA2593715A patent/CA2593715C/en not_active Expired - Fee Related
- 2006-01-26 BR BRPI0607299-2A patent/BRPI0607299A2/pt not_active IP Right Cessation
- 2006-01-26 EP EP06733921.8A patent/EP1848813B1/en not_active Expired - Lifetime
- 2006-01-26 JP JP2007553225A patent/JP5053101B2/ja not_active Expired - Fee Related
- 2006-01-26 PT PT67339218T patent/PT1848813E/pt unknown
- 2006-01-26 US US11/814,103 patent/US9295722B2/en not_active Expired - Fee Related
-
2007
- 2007-07-26 ZA ZA200706208A patent/ZA200706208B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12264170B2 (en) | Antimicrobial organosilanes | |
| JP7512329B2 (ja) | プロバイオティクス／プレバイオティクス有効成分を含む清浄剤組成物 | |
| WO2006083671B1 (en) | Bacterial glycolipid activation of cd1d-restricted nkt cells | |
| WO2010006315A3 (en) | Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and intiviral, antibacterial, and anticancer agents | |
| CN105362212A (zh) | 一种免洗手消毒凝胶及其制备方法 | |
| NZ590472A (en) | Ophthalmic device having therapeutic agent delivery capability and method of forming same | |
| NZ591103A (en) | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides | |
| RU2016109925A (ru) | Адъюванты на масляной основе | |
| JP2011525911A5 (enExample) | ||
| TW200911274A (en) | Alpha-galatosyl ceramide analogs and their use as immunotherapies | |
| JP2021503029A5 (enExample) | ||
| CA3018987A1 (en) | Topical cleansing composition with prebiotic/probiotic additive | |
| JP2009504660A5 (enExample) | ||
| CA2874508C (en) | Aqueous alcoholic microbicidal compositions comprising zinc ions | |
| De Carvalho et al. | Chitosan as an oral antimicrobial agent | |
| JP2007045732A5 (enExample) | ||
| WO2009102808A3 (en) | Doxorubicin adjuvants to reduce toxicity and methods for using the same | |
| JP2008509939A5 (enExample) | ||
| RU2010141977A (ru) | Циклическое соединение и его соль | |
| Sultan et al. | Management of Enterococcus faecalis associated endodontic infection using gold nanogel: An in-vitro study | |
| PH12012501674A1 (en) | Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof | |
| JP2015528509A5 (enExample) | ||
| Inoue et al. | Antibacterial characteristics of newly developed amphiphilic lipids and DNA–lipid complexes against bacteria | |
| CN101972272B (zh) | 一种二氧化氯皮肤凝胶及其制备方法 | |
| WO2003049670A3 (en) | Adjuvant formulations for bacterial and virus vaccines and method of making same |